Title : Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine.

Pub. Date : 2006 Aug

PMID : 16918719






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Lidocaine is metabolized by cytochrome P450 3A4 (CYP3A4) and CYP1A2 enzymes, but inhibitors of CYP3A4 have had only a minor effect on its pharmacokinetics. Lidocaine cytochrome P450 family 3 subfamily A member 4 Homo sapiens
2 Lidocaine is metabolized by cytochrome P450 3A4 (CYP3A4) and CYP1A2 enzymes, but inhibitors of CYP3A4 have had only a minor effect on its pharmacokinetics. Lidocaine cytochrome P450 family 3 subfamily A member 4 Homo sapiens
3 Lidocaine is metabolized by cytochrome P450 3A4 (CYP3A4) and CYP1A2 enzymes, but inhibitors of CYP3A4 have had only a minor effect on its pharmacokinetics. Lidocaine cytochrome P450 family 3 subfamily A member 4 Homo sapiens
4 We studied the effect of co-administration of fluvoxamine (CYP1A2 inhibitor) and erythromycin (CYP3A4 inhibitor) on the pharmacokinetics of lidocaine in a double-blind, randomized, three-way cross-over study. Lidocaine cytochrome P450 family 3 subfamily A member 4 Homo sapiens
5 The concomitant use of both fluvoxamine and a CYP3A4 inhibitor like erythromycin may further increase plasma lidocaine concentrations. Lidocaine cytochrome P450 family 3 subfamily A member 4 Homo sapiens